ABVC BioPharma
ABVC
15 hedge funds and large institutions have $1.72M invested in ABVC BioPharma in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 5 closing their positions.
117% more capital invested
Capital invested by funds: $792K → $1.72M (+$930K)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
15% more funds holding
Funds holding: 13 → 15 (+2)
0.98% more ownership
Funds ownership: 3.21% → 4.19% (+0.98%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$229K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$89.8K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$60.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$45.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$40.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$92.3K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$20.4K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$11.9K |
| 4 |
Squarepoint
New York
|
-$10.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.26K |
ABVC Hedge Fund Activity: Q2 2026 in Review
15 of the 8,329 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2026, worth a combined $1.72M — up 117% from $792K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ABVC positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Capital Management, adding an estimated $229K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $92.3K sold.
- 15 institutional investors held ABVC BioPharma (ABVC) as of Q2 2026, up from 13 in Q1 2026.
- Funds reported $1.72M of ABVC BioPharma stock for Q2 2026, up 117% quarter-over-quarter.
- 7 funds opened new ABVC BioPharma positions in Q2 2026 and 5 closed out, a net change of +2 holders.
- The largest ABVC BioPharma buyer in Q2 2026 was Vanguard Capital Management, an estimated $229K added.
- The largest ABVC BioPharma seller in Q2 2026 was Renaissance Technologies, an estimated $92.3K sold.
Based on aggregated 13F filings for Q2 2026.